News
GlobalData on MSN2mon
Palatin concludes Phase II trial of combination therapy for obesitya glucagon-like peptide-1 (GLP-1)/gastric inhibitory polypeptide (GIP), to treat obesity. The final output collection and ...
Hosted on MSN6mon
Amgen downgraded at Truist on MariTide prospects for obesityAnalyst Robyn Karnauskas wrote that when phase 2 data on MariTide, a GLP-1 receptor and gastric inhibitory polypeptide receptor comes out, it will likely reflect prior data. And given the current ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback